Oncobiologics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.01 EPS

Oncobiologics (NASDAQ:OTLK) issued its quarterly earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01), FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.97 million.

Here are the key takeaways from Oncobiologics’ conference call:

• FDA approval secured for LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S., positioning Outlook Therapeutics to target the established market for repackaged off-label bevacizumab.
• Management is targeting more than $500 million in peak U.S. annual sales by 2030, with potential upside of nearly $300 million if compounded bevacizumab availability is disrupted. The company expects a first-year U.S. revenue ramp of $50 million-$75 million, accelerating after an anticipated permanent J-code in April 2027.
• The company plans a measured U.S. launch later this year, including approximately 30 customer-facing commercial hires and 20 field reimbursement personnel. It expects LYTENAVA’s wholesale acquisition price to be below $500 per vial and is preparing payer engagement, supply, and coding infrastructure.
• Outlook reported only $11.2 million in cash at June 30, although a subsequent $55 million offering is expected to provide approximately $51.1 million in net proceeds. Quarterly SG&A is expected to roughly double by the end of 2026 and rise another 10% in 2027 to support commercialization.
• European commercialization remains challenging because of reimbursement constraints, pricing pressure, and local compounding practices. Management expects Europe to represent less than one-quarter of the U.S. opportunity by 2030, despite improving unit sales and planned expansion into additional markets.

Oncobiologics Trading Down 14.9%

NASDAQ OTLK traded down $0.13 during trading on Friday, reaching $0.76. 104,469,209 shares of the company’s stock were exchanged, compared to its average volume of 17,814,098. Oncobiologics has a fifty-two week low of $0.16 and a fifty-two week high of $3.39. The company’s fifty day simple moving average is $1.31 and its 200-day simple moving average is $0.70.

Insider Activity

In other Oncobiologics news, Director Faisal Ghiath Sukhtian bought 95,398 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were bought at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the acquisition, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ghiath M. Sukhtian purchased 8,539,709 shares of Oncobiologics stock in a transaction dated Thursday, May 28th. The stock was bought at an average cost of $0.59 per share, with a total value of $5,038,428.31. Following the completion of the transaction, the director directly owned 22,092,068 shares of the company’s stock, valued at $13,034,320.12. This represents a 63.01% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 8,664,107 shares of company stock worth $5,162,666. Company insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Oncobiologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OTLK. AQR Capital Management LLC boosted its stake in shares of Oncobiologics by 42.7% during the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after buying an additional 25,351 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after acquiring an additional 44,063 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after acquiring an additional 21,941 shares during the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

OTLK has been the subject of several recent analyst reports. Wall Street Zen upgraded shares of Oncobiologics from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. HC Wainwright upped their price target on shares of Oncobiologics to $1.60 and gave the company a “neutral” rating in a research report on Monday, July 27th. Ascendiant Capital Markets raised their price objective on shares of Oncobiologics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Finally, BTIG Research reiterated a “buy” rating and set a $4.00 price objective on shares of Oncobiologics in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $4.65.

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.